Celsion Corporation (CLSN)
| Market Cap | 92.62M |
| Revenue (ttm) | 500,000 |
| Net Income (ttm) | -21.48M |
| Shares Out | 31.96M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $1.06 |
| Previous Close | $1.07 |
| Change ($) | -0.01 |
| Change (%) | -0.84% |
| Day's Open | 1.06 |
| Day's Range | 1.03 - 1.08 |
| Day's Volume | 832,188 |
| 52-Week Range | 0.43 - 6.50 |
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that...
Penny stocks are in focus once again as the hype around Doge Coin ramps up The post Top Penny Stocks Today? 3 Cheap Stocks to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | P...
Lawrenceville, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering ...
Celsion Corporation (NASDAQ: CLSN) has announced a poster highlighting its ongoing Phase 1/2 OVATION 2 Study with GEN-1 in advanced ovarian cancer was presented last week at the Virtual Annual Meeting o...
Company reports further strengthening of R0 resection results in patients treated with GEN-1
Virtra Inc (NASDAQ: VTSI) shares are trading lower by 22% Wednesday after the company priced a registered direct offering at $6 per share. VirTra is engaged in the sale and development of the judgmental...
LAWRENCEVILLE, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional invest...
Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet
Wednesday afternoon's and Thursday morning's noteworthy earnings reports were included in our Tuesday preview covering scheduled reports from electric pickup maker Lordstown Motors, cannabis producers S...
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today an...
LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today ann...
Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GEN-1 is a D...
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years
Celsion (CLSN) stock was on the rise Monday after announcing fast-track approval from the U.S. Food and Drug Administration. The post CLSN Stock: Why Biotech Celsion Is Soaring Today appeared first on I...
Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2
Celsion (CLSN) stock is rising higher on Thursday after the release of a letter from chairman, president and CEO Michael Tardugno. The post CLSN Stock: Why Biotech Company Celsion Is Soaring Today appea...
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct o...
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investo...
Celsion Corporation (NASDAQ: CLSN) shares are trading at their highest level since early July after the company terminated a stock sale agreement. Celsion revealed in SEC filing it has notified Lincoln ...
Celsion (CLSN) stock is soaring higher Thursday on heavy trading and InvestorPlace has all the details investors need to know. The post CLSN Stock Alert: 5 Things to Know About Celsion as Shares Soar ap...
Shares of Celsion Corp. shot up 85.1% toward a six-month high in very active premarket trading Thursday, putting the on track to more than double in two days, after the cancer drug development company d...
LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation.
LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Celsion" or "t...
New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November ...
NEW YORK, Dec. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015...
New York, New York--(Newsfile Corp. - December 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November ...
NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from...
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10...
New York, New York--(Newsfile Corp. - December 15, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November...
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from...
New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company")...
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN)...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015...
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and Jul...
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: CLSN) from...
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and July 10,...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NASDAQ: CLSN)...
New York, New York--(Newsfile Corp. - December 5, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November ...
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 and Jul...
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: CLSN). The...
New York, New York--(Newsfile Corp. - November 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November...
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge ...
About CLSN
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers. Celsion Corporation was founded in 1982 and i... [Read more...]
| Industry Biotechnology | IPO Date Mar 5, 1985 |
| CEO Michael Tardugno | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol CLSN |
Financial Performance
In 2020, Celsion's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$21.48 million, 27.5% more than in 2019.
Analyst Forecasts
According to one analyst, the rating for Celsion stock is "Strong Buy" and the 12-month stock price forecast is 4.50.